Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lipid-altering drugs in development.

H E Bays1, C A Dujovne

  • 1Louisville Metabolic and Atherosclerosis Research Center, Nortons Audubon Hospital, Kentucky, USA.

Drugs in R&D
|November 24, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Weight and cardiometabolic effects of a novel oral shape-shifting superabsorbent hydrogel capsule: Prespecified and exploratory analysis of the Epitomee capsule RESET study.

Obesity pillars·2025
Same author

Chitin-glucan fiber effects on oxidized low-density lipoprotein: a randomized controlled trial.

European journal of clinical nutrition·2012
Same author

Rate and risk predictors for development of self-reported type-2 diabetes mellitus over a 5-year period: the SHIELD study.

International journal of clinical practice·2012
Same author

Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.

Drugs of today (Barcelona, Spain : 1998)·2012
Same author

What men should know about metabolic syndrome, adiposopathy and 'sick fat'.

International journal of clinical practice·2010
Same author

The Bile Acid Sequestrant Acceptability scale validation study.

International journal of clinical practice·2010
Same journal

Gabapentin Extended Release Tablets in Healthy Subjects Under Fed Conditions: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study.

Drugs in R&D·2026
Same journal

Development and Optimization of a Biphasic-Release Acetazolamide Tablet-in-Tablet Formulation.

Drugs in R&D·2026
Same journal

A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors.

Drugs in R&D·2026
Same journal

Ustekinumab in the Management of Perianal Fistulizing Crohn's Disease: Current Evidence and Practical Strategies.

Drugs in R&D·2026
Same journal

HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance.

Drugs in R&D·2026
Same journal

Arylpiperazine Derivative NAF19 Inhibits Prostate Cancer Activity and Its Molecular Mechanisms.

Drugs in R&D·2026
See all related articles

Researchers are exploring new lipid-lowering therapies beyond statins, including drugs affecting lipid absorption and high-density lipoprotein-cholesterol (HDL-C) metabolism, to improve efficacy and tolerability.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Metabolic Disorders

Background:

  • Current lipid-lowering therapies, including statins, are effective but have limitations.
  • There is an ongoing need for treatments with improved efficacy and tolerability.
  • Novel therapeutic strategies are being investigated to manage dyslipidemia.

Purpose of the Study:

  • To review emerging lipid-lowering therapies.
  • To explore new targets beyond HMG-CoA reductase.
  • To discuss agents affecting lipid absorption and HDL-C metabolism.

Main Methods:

  • Literature review of current and investigational lipid-lowering treatments.
  • Analysis of pharmacological mechanisms of novel drug classes.
  • Evaluation of clinical data on agents like orlistat, niacin, and HDL-C modulators.

Related Experiment Videos

Main Results:

  • Orlistat, an antiobesity drug, demonstrates favorable effects on blood lipid profiles.
  • Niacin and drugs targeting HDL-C metabolism are under investigation for therapeutic potential.
  • Inhibitors of enzymes other than HMG-CoA reductase represent a new class of lipid-lowering agents.

Conclusions:

  • New therapeutic avenues for lipid management are being actively researched.
  • Focus is expanding to include lipid absorption and HDL-C enhancement.
  • Future treatments aim for superior efficacy and tolerability in cardiovascular risk reduction.